Detail akcie Biomarin Pharma online

Business Summary: BioMarin Pharmaceutical Inc. (BioMarin) is a biotechnology company, which is engaged in developing and commercializing therapies that address the root cause of genetic conditions. BioMarin's commercial products include Vimizim (elosulfase alpha), Naglazyme (galsulfase), Palynziq (pegvaliase-pqpz), Brineura (cerliponase alfa), Aldurazyme (laronidase), Roctavian (valoctocogene roxaparvovec), Kuvan (sapropterin dihydrochloride), and Voxzogo (vosoritide). Vimizim is an enzyme replacement therapy for the treatment of MPS IVA, a lysosomal storage disorder. The Roctavian is an adeno associated virus (AAV5) vector gene therapy designed to restore factor VIII plasma concentrations in patients with severe hemophilia A. Voxzogo is a once daily injection analog of C-type Natriuretic Peptide (CNP) for the treatment of achondroplasia. Brineura is a recombinant human tripeptidyl peptidase 1 (TPP1) for the treatment of patients with CLN2, a form of Batten disease.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2023, Biomarin Pharmaceutical Inc revenues increased 15% to $2.42B. Net income increased 18% to $167.6M. Revenues reflect Voxzogo segment increase from $169.1M to $469.9M, Palynziq1 segment increase of 19% to $303.9M, Rest of the world segment increase of 50% to $468.2M, United States segment increase of 13% to $771.3M. Net income benefited from Interest Income increase from $18M to $58.3M (income).